Process for preparing pneumococcal polysaccharide-protein conjugates
An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection.
1. A multivalent immunogenic composition comprising polysaccharide-protein conjugates and a physiologically acceptable vehicle, wherein each of the conjugates comprises a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to a carrier protein, wherein the serotypes comprise serotype 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F polysaccharides, wherein the carrier protein is CRM197, and wherein the composition is formulated as a 0.5 ml dose comprising 2 μg of each polysaccharide, except for 6B at 4 μg.
2. The immunogenic composition of claim 1 , wherein at least one of the serotype 3, 4, 9V, 14 and 18C polysaccharides were conjugated to the carrier proteins in aqueous solution.
3. The immunogenic composition of claim 2 , wherein the polysaccharides were conjugated using reductive amination.
4. The immunogenic composition of claim 1 , wherein at least one of the serotype 6B, 19F and 23F polysaccharides were conjugated to the carrier proteins in dimethyl sulfoxide (DMSO).
5. The immunogenic composition of claim 4 , wherein the polysaccharides were conjugated using reductive amination.
6. The immunogenic composition of claim 1 , wherein the serotype 1 and 5 polysaccharides were conjugated to the carrier proteins in aqueous solution.
7. The immunogenic composition of claim 1 , wherein the serotype 6A, 7F and 19A polysaccharides were conjugated to the carrier proteins in DMSO.
8. The immunogenic composition of claim 1 , wherein the physiologically acceptable vehicle comprises a buffered saline solution.
9. The immunogenic composition of claim 1 , further comprising an adjuvant.
10. The immunogenic composition of claim 9 , wherein the adjuvant is an aluminum-based adjuvant.
11. The immunogenic composition of claim 10 , wherein the adjuvant is selected from the group consisting of aluminum phosphate, aluminum sulfate and aluminum hydroxide.
12. The immunogenic composition of claim 11 , wherein the adjuvant is aluminum phosphate.
13. The immunogenic composition of claim 12 , wherein the aluminum phosphate is present at 125 μg.
14. The immunogenic composition of claim 1 , further comprising a buffer.
15. The immunogenic composition of claim 1 , wherein the composition further comprises one or more antigens.
16. The immunogenic composition according to claim 15 , wherein said one or more antigens is from a bacteria other than Streptococcus pneumoniae.
17. The immunogenic composition according to claim 16 , wherein said bacteria is selected from the group consisting of nontypable Haemophilus influenza, Moraxella catarrhalis and Alloiococcus otitidis.
18. The immunogenic composition of claim 1 , wherein the composition further comprises one or more proteins from Streptococcus pneumoniae.
19. The immunogenic composition of claim 1 , wherein the composition further comprises one or more proteins from Neisseria meningitidis type B.